TYPE 1 DIABETES MELLITUS

✓ Medically ReviewedDISEASEID: MDBT0260🚨 TRIAGE: EMERGENCYICD-10: E10

📖

Definition

CLINICAL DEFINITION

Type 1 diabetes mellitus is a chronic metabolic disorder characterised by hyperglycaemia resulting from absolute insulin deficiency due to immune-mediated destruction of pancreatic β-cells. It accounts for approximately 5–10% of all cases of diabetes and requires lifelong exogenous insulin replacement for survival. The disease has strong HLA associations, and the presence of multiple islet autoantibodies (such as GAD65, IA-2, ZnT8, and insulin autoantibodies) is a hallmark of the autoimmune subtype.

IN PLAIN ENGLISH

Type 1 diabetes is a condition where the body's immune system mistakenly attacks the cells in the pancreas that make insulin. Without insulin, sugar builds up in the blood because it cannot enter cells to be used for energy. People with type 1 diabetes need to take insulin every day to stay alive.

COMMON MISCONCEPTION / WHAT IT DOES NOT MEAN

Type 1 diabetes mellitus is NOT the same as type 2 diabetes, which is characterised by insulin resistance and relative (not absolute) insulin deficiency and does not typically require insulin for survival at onset. It is also distinct from monogenic diabetes (such as MODY) and secondary causes of diabetes, which have different genetic and pathophysiological mechanisms.

🔤

Word Breakdown

diabetes

=From Greek 'diabētēs' (siphon) and Latin 'mellitus' (honey-sweet)

Literal Meaning: A condition of excessive urine production sweetened by sugar

🏷️

Abbreviations

T1DM=Type 1 Diabetes Mellitus — the standard abbreviation used in clinical documentation.

T1D=Type 1 Diabetes — a common shorthand used in research literature and clinical practice.

IDDM=Insulin-Dependent Diabetes Mellitus — an older term reflecting the absolute requirement for exogenous insulin.

🔄

Synonyms & Variants

Insulin-Dependent Diabetes Mellitus›Juvenile-Onset Diabetes›Type 1 Diabetes›

🎯

Category-Specific Context

As a Disease, type 1 diabetes mellitus is classified within the spectrum of diabetes mellitus, which also includes type 2 diabetes, gestational diabetes, and specific types due to other causes. The current staging framework recognises three preclinical stages: Stage 1 (multiple islet autoantibodies with normoglycaemia), Stage 2 (autoantibodies with dysglycaemia not meeting diabetes criteria), and Stage 3 (clinical diabetes with symptoms and/or ketoacidosis). This classification reflects the underlying autoimmune pathobiology and guides screening and early intervention.

🏥

Clinical Context & Usage

CLINICAL SETTINGS

Endocrinology Outpatient ClinicPaediatric Diabetes ClinicEmergency DepartmentGeneral Medicine WardIntensive Care UnitPrimary Care

USAGE & DOCUMENTATION NOTES

In clinical documentation, type 1 diabetes is often recorded as 'T1DM' or 'T1D' in problem lists and referral letters. When documenting management, clinicians specify the insulin regimen (e.g., 'basal-bolus regimen with insulin glargine and insulin aspart') and glycaemic targets. The term is frequently used in the context of 'new-onset T1DM' or 'established T1DM' to distinguish disease duration. In paediatric notes, 'T1DM' is typically used alongside growth parameters and HbA1c values.

🔬

Primary Causes & Pathophysiology

PATHOPHYSIOLOGY

Type 1 diabetes mellitus arises from T-cell-mediated autoimmune destruction of pancreatic β-cells in genetically susceptible individuals. The process begins with the loss of self-tolerance, leading to insulitis (inflammation of the islets) and progressive β-cell death. This destruction proceeds subclinically for months to years; clinical hyperglycaemia typically manifests when approximately 80–90% of β-cells have been destroyed. The loss of insulin secretion results in impaired glucose uptake by peripheral tissues (muscle and adipose) and unrestrained hepatic glucose production. In the absence of insulin, counter-regulatory hormones (glucagon, adrenaline, cortisol, and growth hormone) are secreted in excess, promoting gluconeogenesis, glycogenolysis, and ketogenesis. This leads to hyperglycaemia and, when severe, to anion-gap metabolic acidosis with ketonaemia (diabetic ketoacidosis). Long-term hyperglycaemia causes vascular complications through protein glycosylation, sorbitol accumulation, and oxidative stress, affecting both microvasculature (retinopathy, nephropathy, neuropathy) and macrovasculature (coronary, cerebrovascular, and peripheral arterial disease).

PRIMARY CAUSES

Autoimmune β-cell destruction (type 1A diabetes)

T-cell-mediated immune attack against pancreatic β-cells in genetically susceptible individuals (HLA-DR/DQ alleles), leading to progressive insulin deficiency.

Idiopathic type 1 diabetes (type 1B diabetes)

β-cell destruction without evidence of autoimmune markers; the underlying mechanism is less well defined and may involve alternative pathways of β-cell loss.

💊

Drug-Induced Causes

💊 Immune checkpoint inhibitors (e.g., nivolumab, pembrolizumab, ipilimumab) ↗

Mechanism: Checkpoint inhibition unleashes T-cell-mediated immune attack against pancreatic β-cells, precipitating fulminant type 1 diabetes, often with ketoacidosis and low C-peptide.

→ Monitor glucose closely during and after checkpoint inhibitor therapy; if diabetes develops, initiate insulin therapy and manage ketoacidosis if present. Corticosteroids are generally not effective for this immune-related adverse event.

🌍

Epidemiology

Prevalence:Type 1 diabetes affects approximately 9 million people globally, including over 1.5 million children. In 2024, there were over 500,000 new diagnoses worldwide. The global prevalence is estimated to range from 0.8 to 4.6 per 1,000 population, with significant regional variation; incidence is highest in Northern European countries such as Finland and lowest in parts of Asia. In most populations, type 1 diabetes accounts for 5–10% of all diabetes cases.

Age Group:Type 1 diabetes can present at any age, but incidence peaks in childhood and early adulthood, with the highest incidence observed in children aged 10–14 years. Two childhood diagnosis peaks occur at ages 4–7 years and 10–14 years. Adult-onset type 1 diabetes also occurs and may be misclassified as type 2 diabetes; latent autoimmune diabetes in adults (LADA) is a slower-progressing form.

Sex Predilection:Male

Geographic Distribution:The incidence of type 1 diabetes varies markedly by geography, with the highest rates in Northern Europe (particularly Finland) and the lowest in parts of Asia and South America. White European populations have the highest rates, but increases are occurring in other ethnic groups. The global incidence is rising, particularly in non-white racial and ethnic groups.

Red Flags & Triage ★

TRIAGE LEVEL

🚨 EMERGENCY

DO NOT MISS — LIFE-THREATENING PRESENTATIONS

Diabetic ketoacidosis (DKA) — consider in any patient with type 1 diabetes presenting with nausea, vomiting, abdominal pain, Kussmaul breathing, or altered consciousness; check blood glucose and ketones urgently and initiate treatment.
Severe hypoglycaemia — consider in any patient with type 1 diabetes presenting with confusion, seizures, or loss of consciousness; check blood glucose immediately and treat with intravenous glucose or glucagon if needed.

URGENT EVALUATION TRIGGERS

Blood ketones ≥3 mmol/L or significant ketonuria with hyperglycaemia — immediate assessment for DKA
Persistent vomiting, abdominal pain, or inability to maintain oral intake — risk of dehydration and DKA
Kussmaul breathing or any degree of altered mental status — immediate emergency assessment
Blood glucose persistently >15 mmol/L with symptoms of hyperglycaemia despite insulin — same-day review

Contraindications & Precautions

CONTRAINDICATIONS

Do not withhold insulin therapy in a patient with type 1 diabetes
even during illness or when not eating
without specialist guidance
as this risks diabetic ketoacidosis.

SPECIAL PRECAUTIONS

Monitor for hypoglycaemia
especially in patients with impaired awareness of hypoglycaemia or tight glycaemic targets.
Assess for associated autoimmune conditions (thyroid dysfunction
coeliac disease
adrenal insufficiency) at diagnosis and periodically thereafter.
Provide sick-day rules education
including ketone monitoring and when to seek urgent care.
Ensure appropriate vaccination status
particularly against influenza and pneumococcal infection
which can precipitate metabolic decompensation.

Complications

DOWNSTREAM CLINICAL COMPLICATIONS

Diabetic ketoacidosis (DKA) — absolute insulin deficiency leads to ketogenesis and metabolic acidosis; a life-threatening emergency.
Hypoglycaemia — most common acute complication of insulin therapy; can be severe and cause seizures or loss of consciousness.
Microvascular complications — retinopathy (leading cause of blindness in working-age adults)
nephropathy (leading cause of end-stage renal disease)
and neuropathy (peripheral and autonomic).
Macrovascular complications — coronary artery disease
cerebrovascular disease
and peripheral arterial disease
occurring at a younger age than in the general population.
Association with other autoimmune diseases — thyroid disease (Hashimoto thyroiditis
Graves disease)
coeliac disease
Addison disease
and pernicious anaemia.

🔀

Confused With (LASA & DDx) ★

LEXICAL (LASA) — SIMILAR NAMES

Type 2 Diabetes Mellitus

Both are major types of diabetes mellitus; however, type 2 is characterised by insulin resistance and relative insulin deficiency, whereas type 1 is characterised by absolute insulin deficiency. Confusing them can lead to inappropriate management (e.g., withholding insulin in type 1).

Diabetes Insipidus

Shares the name 'diabetes' but is a disorder of antidiuretic hormone (ADH) secretion or action, causing polyuria and polydipsia without hyperglycaemia. Confusion can lead to unnecessary glucose testing and delayed diagnosis of the actual condition.

CLINICAL DIFFERENTIAL DIAGNOSES (DDx)

Type 2 Diabetes Mellitus

Key Distinguishing Feature: Older age at onset, obesity, insulin resistance, absence of islet autoantibodies, and preserved C-peptide initially; does not typically require insulin for survival at onset.

Latent Autoimmune Diabetes in Adults (LADA)

Key Distinguishing Feature: Adult-onset autoimmune diabetes with a slower progression to insulin dependence; positive islet autoantibodies (especially GAD65) and lower C-peptide than type 2 diabetes; age at onset often <50 years, BMI <25 kg/m², and personal/family history of autoimmune disease.

Maturity-Onset Diabetes of the Young (MODY)

Key Distinguishing Feature: Monogenic diabetes with autosomal dominant inheritance, onset typically before age 25 years, absence of islet autoantibodies, and preserved endogenous insulin secretion. Genetic testing confirms the diagnosis.

Secondary Diabetes (e.g., pancreatic diabetes, cystic fibrosis-related diabetes, drug-induced)

Key Distinguishing Feature: Diabetes occurring in the context of a known underlying condition (e.g., chronic pancreatitis, cystic fibrosis, glucocorticoid therapy, checkpoint inhibitor therapy). The clinical context and absence of typical autoimmune markers help distinguish it from type 1 diabetes.

💎

Clinical Pearls

💎

Type 1 diabetes is an autoimmune disease; the presence of multiple islet autoantibodies (e.g., GAD65, IA-2, ZnT8) confirms the diagnosis and distinguishes it from type 2 diabetes, even in adults with a BMI >25 kg/m².

💎

A honeymoon phase (partial remission) can occur after insulin initiation, with reduced insulin requirements for months; however, insulin should never be completely stopped, and patients remain at risk of DKA.

💎

Children and adolescents with new-onset type 1 diabetes often present with DKA; a high index of suspicion is required for polyuria, polydipsia, and weight loss, even in the absence of a family history.

💎

Basal-bolus insulin regimens (long-acting basal insulin plus rapid-acting prandial insulin) are the preferred approach for most patients with type 1 diabetes, allowing flexibility in meal timing and reducing hypoglycaemia risk compared with fixed-dose regimens.

💎

Patients with type 1 diabetes are at increased risk of other autoimmune diseases (thyroid, coeliac, adrenal); screening for thyroid dysfunction and coeliac disease should be performed at diagnosis and periodically thereafter.

📝

Example Usage & SOAP

CLINICAL SENTENCE

""12-year-old girl with a 2-week history of polyuria, polydipsia, and 3 kg weight loss; random plasma glucose 22.1 mmol/L, blood ketones 4.2 mmol/L, pH 7.18 — admitted with new-onset type 1 diabetes mellitus and diabetic ketoacidosis.""

IN A SOAP NOTE

S: 12-year-old girl brought in by parents with 2 weeks of excessive thirst, frequent urination, and unintentional weight loss. Over the past 24 hours she has developed nausea and abdominal pain. O: Vitals: HR 118 bpm, BP 98/60 mmHg, RR 28 breaths/min (deep), SpO2 98% on room air. Weight 38 kg (previously 41 kg). Capillary glucose 24.5 mmol/L. Blood ketones 4.8 mmol/L. Venous blood gas: pH 7.15, bicarbonate 10 mmol/L, anion gap 22. Urine dipstick: glucose +++, ketones +++. A: New-onset type 1 diabetes mellitus complicated by diabetic ketoacidosis. P: Admit to paediatric high-dependency unit. Initiate intravenous fluid resuscitation with 0.9% sodium chloride. Start fixed-rate intravenous insulin infusion at 0.05 units/kg/hour. Monitor capillary glucose and blood ketones hourly. Once ketones <0.5 mmol/L and pH normalised, transition to subcutaneous basal-bolus insulin (insulin glargine 10 units once daily and insulin aspart with meals). Diabetes specialist nurse referral for education.

DIFFERENTIAL DIAGNOSIS CONTEXT

Differential for type 1 diabetes mellitus: (1) Type 2 diabetes mellitus — suggested by older age, obesity, absence of autoantibodies, and preserved C-peptide; (2) Latent autoimmune diabetes in adults (LADA) — suggested by adult onset, positive GAD65 antibodies, and slower progression to insulin dependence; (3) Maturity-onset diabetes of the young (MODY) — suggested by autosomal dominant family history, young onset, absence of autoantibodies, and preserved C-peptide; (4) Secondary diabetes — suggested by a history of pancreatic disease, cystic fibrosis, or use of diabetogenic medications such as glucocorticoids or checkpoint inhibitors.

📊

Classifications & Scoring

STAGING SCALE

Staging of Presymptomatic Type 1 Diabetes (ADA/JDRF/Endocrine Society)

Three-stage classification of presymptomatic type 1 diabetes: Stage 1 (≥2 islet autoantibodies with normoglycaemia), Stage 2 (≥2 islet autoantibodies with dysglycaemia not meeting diabetes criteria), and Stage 3 (clinical diabetes with symptoms and/or ketoacidosis).

Scale Reference ↗

SCORING TOOL

Diabetes Prevention Trial-Type 1 Risk Score (DPTRS)

A risk score used in research settings to predict progression to clinical type 1 diabetes in individuals with islet autoantibodies; incorporates age, BMI, glucose, and C-peptide measures.

Clinical Calculator ↗

📈

Prognosis

SHORT-TERM OUTCOME

With appropriate insulin therapy and education, most patients can achieve glycaemic control and avoid acute emergencies. However, new-onset type 1 diabetes frequently presents with diabetic ketoacidosis, which carries a mortality risk of approximately 0.15–0.3% even with treatment. Intensive glycaemic control reduces the incidence and progression of microvascular complications.

LONG-TERM PROGNOSIS

Long-term prognosis depends on glycaemic control and access to comprehensive care. Intensive insulin therapy reduces the risk of microvascular and macrovascular complications, and the benefits of early intensive control persist for decades ('metabolic memory'). Cardiovascular disease is the leading cause of mortality in long-term type 1 diabetes, accounting for approximately two-thirds of deaths by the third decade of disease. Overall mortality is increased compared with the general population, particularly in those with poor glycaemic control or recurrent DKA.

📚

References & Coding

ICD-10 DIAGNOSTIC CODE

E10

LITERATURE CITATIONS & GUIDELINES

[1]American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2025. Diabetes Care. 2025;48(Supplement_1):S27–S49. doi:10.2337/dc25-S002

[2]Bell KJ, et al. The Changing Epidemiology of Type 1 Diabetes: A Global Perspective. Diabetes Obes Metab. 2025;27(Suppl 6):3–14. doi:10.1111/dom.16501

[3]International Society for Pediatric and Adolescent Diabetes (ISPAD). ISPAD Clinical Practice Consensus Guidelines 2022: Type 1 Diabetes in Children and Adolescents. Pediatr Diabetes. 2022;23(8):1161–1202.

[4]World Health Organization. ICD-10: International Statistical Classification of Diseases and Related Health Problems, 10th Revision. Geneva: WHO; 2019. Code E10.

MEDICAL DISCLAIMER — This content is intended for educational purposes and qualified healthcare professionals only. Always refer to current clinical diagnostic criteria, institutional protocols, and official guidelines. Medobo is not responsible for clinical decisions made based on this content.